Based on the critical roles of the RANK/RANKL system during the progression of initial primary breast cancer and subsequently bone metastasis, inhibition of RANKL has been developed as a novel therapeutic strategy for advanced breast cancer. Here, TNFRSF11A is linked to breast cancer.